StockMacro
Menu

Medical Properties Trust

$1.75 -65% in 6 monthsMarket cap $1.0B

MPT on XNYS, Real Estate, Medical Properties Trust, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 66% in six months, with 25% of the shares sold short.

  • BadNet loss $125.9M over 12 months despite 5.5% revenue growth
  • WatchNet debt $9.2B on the balance sheet, with cash of $425M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 31 Mar 2026

Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.

Industry
Real estate investment trusts (Real Estate)
Employees
121
Website
mpt.com
Listed
NYSE, US
Last results
29 Oct 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 31 Mar 2026: revenue $252.1M, net income $32.8M.
Quarter to 31 Dec 2021: revenue $409.3M, net income $206.5MQuarter to 31 Dec 2021: revenue $409.3M, net income $206.5MQuarter to 31 Mar 2022: revenue $409.8M, net income $631.7MQuarter to 31 Mar 2022: revenue $409.8M, net income $631.7MQuarter to 30 Jun 2022: revenue $400.2M, net income $189.6MQuarter to 30 Jun 2022: revenue $400.2M, net income $189.6MQuarter to 30 Sep 2022: revenue $352.3M, net income $221.8MQuarter to 30 Sep 2022: revenue $352.3M, net income $221.8MQuarter to 31 Dec 2022: revenue $380.5M, net income -$140.5MQuarter to 31 Dec 2022: revenue $380.5M, net income -$140.5MQuarter to 31 Mar 2023: revenue $350.2M, net income $32.8MQuarter to 31 Mar 2023: revenue $350.2M, net income $32.8MQuarter to 30 Jun 2023: revenue $337.4M, net income -$42.0MQuarter to 30 Jun 2023: revenue $337.4M, net income -$42.0MQuarter to 30 Sep 2023: revenue $306.6M, net income $116.7MQuarter to 30 Sep 2023: revenue $306.6M, net income $116.7MQuarter to 31 Dec 2023: revenue –, net income -$663.9MQuarter to 31 Mar 2024: revenue $271.3M, net income -$875.6MQuarter to 31 Mar 2024: revenue $271.3M, net income -$875.6MQuarter to 30 Jun 2024: revenue $266.6M, net income -$320.6MQuarter to 30 Jun 2024: revenue $266.6M, net income -$320.6MQuarter to 30 Sep 2024: revenue $225.8M, net income -$801.2MQuarter to 30 Sep 2024: revenue $225.8M, net income -$801.2MQuarter to 31 Dec 2024: revenue $231.8M, net income -$412.8MQuarter to 31 Dec 2024: revenue $231.8M, net income -$412.8MQuarter to 31 Mar 2025: revenue $223.8M, net income -$118.3MQuarter to 31 Mar 2025: revenue $223.8M, net income -$118.3MQuarter to 30 Jun 2025: revenue $240.4M, net income -$98.4MQuarter to 30 Jun 2025: revenue $240.4M, net income -$98.4MQuarter to 30 Sep 2025: revenue $237.5M, net income -$77.7MQuarter to 30 Sep 2025: revenue $237.5M, net income -$77.7MQuarter to 31 Dec 2025: revenue $270.3M, net income $17.3MQuarter to 31 Dec 2025: revenue $270.3M, net income $17.3MQuarter to 31 Mar 2026: revenue $252.1M, net income $32.8MQuarter to 31 Mar 2026: revenue $252.1M, net income $32.8M
31 Dec 2021RevenueNet incomeNet losstallest bar $875.6M31 Mar 2026
See the numbers
Quarter toRevenueNet income
31 Mar 2026$252.1M$32.8M
31 Dec 2025$270.3M$17.3M
30 Sep 2025$237.5M-$77.7M
30 Jun 2025$240.4M-$98.4M
31 Mar 2025$223.8M-$118.3M
31 Dec 2024$231.8M-$412.8M
30 Sep 2024$225.8M-$801.2M
30 Jun 2024$266.6M-$320.6M
31 Mar 2024$271.3M-$875.6M
31 Dec 2023–-$663.9M
30 Sep 2023$306.6M$116.7M
30 Jun 2023$337.4M-$42.0M
31 Mar 2023$350.2M$32.8M
31 Dec 2022$380.5M-$140.5M
30 Sep 2022$352.3M$221.8M
30 Jun 2022$400.2M$189.6M
31 Mar 2022$409.8M$631.7M
31 Dec 2021$409.3M$206.5M
Fundamentals, 12 months to 31 Mar 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $1.0B $948.0M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +5.5% +5.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$125.9M -$1.7B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$0.21 -$2.77
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 89.4% 87.9% 68.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – 37.9%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -12.6% -174% 14.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -2.7% 4.4%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $425.0M $673.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $9.7B $9.5B
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $9.2B $8.8B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 2.1 1.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 24.5
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.0 4.5
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 10.3 9.8
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.23 1.1
Dividend yieldDividends per share declared in the latest fiscal year divided by the share price. 18.9% 5.1%

Latest = 12 months to 31 Mar 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Medical Properties TrustMPT (this company) $1.0Bloss1.0+5.5%-12.6%
Ladder CapitalLADR $1.0B10.5–––
Easterly Government PropertiesDEA $1.0B69.42.8+11%4.0%
National Healthcare PropertiesNHP $1.1Bloss3.0+4.6%-3.4%
CenterspaceCSR $923.6M10.23.6-6.0%35.4%
Alexander'sALX $1.2B6.2–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$5K

bought $0, sold $5K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-4.8%

455 13F filers vs 478

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

61%

366.6M shares held by 13F filers (30 Sep 2026) of 598.1M outstanding (6 May 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

25%

148.7M shares sold short (30 Oct 2026) of 598.1M outstanding (6 May 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

7.6

148.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-0.5%

149.4M shares sold short in the report before, 148.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

65%

65% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 58%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$260K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

52

52 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

17×

52 articles in the last 7 days; its usual week has 3.

Price $1.75 on 20 Nov 2026, -66% over 12 months (12-month range $1.50 to $6.02)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $6K in the last 12 months (the 12 months before: -$459K).
Revenue per quarter. Revenue $252.1M in the latest quarter, +13% on a year earlier.
Institutional holders (13F filers). 455 13F filers reported holding it in the latest 13F quarter, +5.8% on a year earlier.
Lobbying spend. Lobbying spend: $260K published in the last 12 months, -30% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Sep 20248-K and other filingsA major agreement ended
17 Sep 20248-K and other filingsAsset write-down (impairment)
16 May 20248-K and other filingsDelisting notice or listing transfer
10 May 20248-K and other filingsReport will be filed late
10 May 20248-K and other filingsAsset write-down (impairment)
18 Apr 20248-K and other filingsA major agreement ended
18 Apr 20248-K and other filingsCompleted an acquisition or asset sale
14 Mar 20248-K and other filingsDirector or officer change
14 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Dec 20238-K and other filingsDirector or officer change
14 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Oct 2023Lobbying filingnew lobbying registration (ACTUM I, LLC)
28 Sep 2023Lobbying filingnew lobbying registration (CASSIDY & ASSOCIATES, INC.)
28 Sep 2023Sharp changeFirst lobbying registration: first lobbying registration: MEDICAL PROPERTIES TRUST: new lobbying registration (CASSIDY & ASSOCIATES, INC.)
23 Feb 20238-K and other filingsDirector or officer change
23 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Feb 2023Sharp changeMany funds opening a new position: many funds opening a new position, 94 vs usual 57.50 (2022-12-31); 1.5x the same period a year earlier
23 Feb 20228-K and other filingsDirector or officer change
23 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: -$122K published
Month from 1 Apr 2022: -$19.1M published
Month from 1 Aug 2024: -$140K published
Month from 1 Sep 2024: $49K published
Month from 1 Oct 2024: -$179K published
Month from 1 Dec 2024: -$54K published
Month from 1 Mar 2025: $43K published
Month from 1 May 2025: -$151K published
Month from 1 Nov 2025: -$296K published
Month from 1 Dec 2025: -$10K published
Month from 1 Aug 2026: $10K published
Month from 1 Nov 2026: -$5K published
Revenue per quarter
Quarter ended 31 Dec 2021: $409.3M, +23% on a year earlier; public on 2 Mar 2022
Quarter ended 31 Mar 2022: $409.8M, +13% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $400.2M, +4.8% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $352.3M, -9.8% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $380.5M, -7.0% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $350.2M, -15% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $337.4M, -16% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $306.6M, -13% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Mar 2024: $271.3M, -23% on a year earlier; public on 30 May 2024
Quarter ended 30 Jun 2024: $266.6M, -21% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $225.8M, -26% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $231.8M; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $223.8M, -18% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $240.4M, -9.8% on a year earlier; public on 9 Aug 2025
Quarter ended 30 Sep 2025: $237.5M, +5.2% on a year earlier; public on 8 Nov 2025
Quarter ended 31 Dec 2025: $270.3M, +17% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $252.1M, +13% on a year earlier; public on 9 May 2026
Institutional holders (13F filers)
31 Dec 2021 report: 548; public on 14 Feb 2022
31 Mar 2022 report: 563; public on 16 May 2022
30 Jun 2022 report: 559; public on 15 Aug 2022
30 Sep 2022 report: 544; public on 14 Nov 2022
31 Dec 2022 report: 577; public on 14 Feb 2023
31 Mar 2023 report: 578; public on 15 May 2023
30 Jun 2023 report: 543; public on 14 Aug 2023
30 Sep 2023 report: 488; public on 14 Nov 2023
31 Dec 2023 report: 514; public on 14 Feb 2024
31 Mar 2024 report: 482; public on 15 May 2024
30 Jun 2024 report: 466; public on 14 Aug 2024
30 Sep 2024 report: 475; public on 14 Nov 2024
31 Dec 2024 report: 447; public on 14 Feb 2025
31 Mar 2025 report: 446; public on 15 May 2025
30 Jun 2025 report: 445; public on 14 Aug 2025
30 Sep 2025 report: 430; public on 14 Nov 2025
31 Dec 2025 report: 459; public on 17 Feb 2026
31 Mar 2026 report: 475; public on 15 May 2026
30 Jun 2026 report: 478; public on 14 Aug 2026
30 Sep 2026 report: 455; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2023: $130K published
Quarter from 1 Jan 2024: $130K published
Quarter from 1 Apr 2024: $130K published
Quarter from 1 Jul 2024: $130K published
Quarter from 1 Oct 2024: $70K published
Quarter from 1 Jan 2025: $70K published
Quarter from 1 Apr 2025: $100K published
Quarter from 1 Jul 2025: $100K published
Quarter from 1 Oct 2025: $100K published
Quarter from 1 Jan 2026: $100K published
Quarter from 1 Oct 2026: $160K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is operating income, fiscal year at $485.6M (31 Dec 2017), 3.5× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders sold a net $6K in the last 12 months (the 12 months before: -$459K).
  • Revenue per quarter: Revenue $252.1M in the latest quarter, +13% on a year earlier.
  • Institutional holders (13F filers): 455 13F filers reported holding it in the latest 13F quarter, +5.8% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 60 insider trades

Last 90 days: 1 sale, $5K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Rosa Handley WilliamsSVP of OperationsSell3,270$1.55$5KForm 4
20 Aug 2026James Kevin HannaSenior VP, Controller & CAOBuy2,300$4.15$10KForm 4
16 Dec 2025Rosa Handley HooperSVP of OperationsSell2,000$5.00$10KForm 4
21 Nov 2025Michael G StewartDirectorSell59,000$5.02$296KForm 4
5 May 2025Michael G StewartDirectorSell29,000$5.20$151KForm 4
6 Mar 2025James Kevin HannaSenior VP, Controller & CAOBuy7,411$5.75$43KForm 4
26 Dec 2024Rosa Handley HooperSVP of OperationsSell3,000$3.67$11KForm 4
26 Dec 2024James Kevin HannaSenior VP, Controller & CAOSell11,641$3.72$43KForm 4

455 institutions reported shares at the end of Q3 2026, 61% of the shares outstanding; 58 opened a position, 80 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.76.4M12.8%$264.4M+1.2M+1.5%
Vanguard Portfolio Management LLC40.1M6.70%$138.6M-3.7M-8.4%
State Street Corp25.6M4.27%$90.7M+398K+1.6%
Vanguard Capital Management LLC21.8M3.65%$75.6M+95K+0.4%
Charles Schwab Investment Management Inc11.7M1.95%$40.3M+140K+1.2%
AQR Capital Management LLC11.2M1.87%$38.8M-6.4M-36%
Geode Capital Management, LLC10.2M1.70%$35.1M+198K+2.0%
Allianz Asset Management GmbH9.5M1.58%$32.7M+2.1M+29%
Citadel Advisors LLC8.8M1.47%$30.4M+7.5M+597%
Morgan Stanley7.5M1.25%$25.8M+683K+10%

Company events

All 53 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
10 Aug 2026Signed a major agreementSame filing: took on new debt8-K
18 Feb 2025Signed a major agreementSame filing: took on new debt8-K
17 Sep 2024A major agreement ended; Asset write-down (impairment)8-K
8 Aug 2024Signed a major agreementSame filing: took on new debt8-K
16 May 2024Delisting notice or listing transfer8-K
10 May 2024Asset write-down (impairment)8-K
10 May 2024Quarterly report will be filed lateNT 10-Q
18 Apr 2024Signed a major agreement; A major agreement ended; Completed an acquisition or asset sale8-K

Reported lobbying spend: $160K in Q3 2026, $100K in Q4 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Aug 2023NewActum I, LLCfor Goodwin Procter, LLP O/B/O Of Medical Properties TrustThe Dodd-Frank Wall Street Reform and Consumer Protection Act, The Securities Exchange Act, Financial Services and General Government Appropriations Act, general REIT issues, general healthcare issuesBudget, Financial institutions, Health issuesFiling
1 Aug 2023NewCassidy & Associates, Inc.for Medical Properties TrustHealthcare reform and modernization effortsBAN, Financial institutions, RES, Health issuesFiling
Timeline

Timeline

Changes and notable records, by the date each became public

  1. 21 Aug 2026Insiders record

    Hanna James Kevin (Senior VP, Controller & CAO) bought 2,300 shares of MPT ($9,545) (dated 20 Aug 2026)

  2. 7 Mar 2025Insiders record

    Hanna James Kevin (Senior VP, Controller & CAO) bought 7,411 shares of MPW ($42,613) (dated 6 Mar 2025)

  3. 20 Sep 2024Insiders record

    Pitman Elizabeth N (director) bought 8,087 shares of MPW ($48,603) (dated 19 Sep 2024)

  4. 17 Sep 2024Filings record

    Asset write-down (impairment)

  5. 17 Sep 2024Filings record

    A major agreement ended

  6. 16 May 2024Filings record

    Delisting notice or listing transfer

  7. 10 May 2024Filings record

    Report will be filed late

  8. 10 May 2024Filings record

    Asset write-down (impairment)

  9. 18 Apr 2024Filings record

    Completed an acquisition or asset sale

  10. 18 Apr 2024Filings record

    A major agreement ended

  11. 14 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 14 Mar 2024Filings record

    Director or officer change

  13. 14 Dec 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  14. 14 Dec 2023Filings record

    Director or officer change

  15. 4 Oct 2023Lobbying record

    GOODWIN PROCTER, LLP O/B/O OF MEDICAL PROPERTIES TRUST: new lobbying registration (ACTUM I, LLC) (dated 30 Aug 2023)

  16. 28 Sep 2023Lobbying change

    registered for federal lobbying for the first time in our data (Cassidy & Associates, Inc.).

    See the evidence (1 source record)
    Source coverage starts
    2 Apr 2009
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  17. 28 Sep 2023Lobbying record

    MEDICAL PROPERTIES TRUST: new lobbying registration (CASSIDY & ASSOCIATES, INC.) (dated 1 Aug 2023)

  18. 23 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 23 Feb 2023Filings record

    Director or officer change

  20. 14 Feb 2023Institutional holdings change

    saw 94 13F filers open a new position in the quarter ended 31 Dec 2022, 1.5× the same quarter last year.

    Same quarter last year: 61; its normal quarter is 57.5.

    See the evidence
    This period
    94 (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    57.5
    Typical spread (median absolute deviation)
    5.5
    How far from its usual level
    +4.5
    Same quarter last year
    61
    History used
    3,379 days
    2020-12-31: 512021-03-31: 602021-06-30: 532021-09-30: 552021-12-31: 612022-03-31: 492022-06-30: 742022-09-30: 682022-12-31: 94
    the quarter ended 31 Dec 20228 earlier quartersnormal: 57.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 23 Feb 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 23 Feb 2022Filings record

    Director or officer change

  23. 11 Aug 2020Financials change

    reported revenue of $291.8M for the quarter ended 30 Jun 2020, 1.5× the same quarter last year.

    Same quarter last year: $192.5M; its normal quarter is $199.4M.

    See the evidence
    This period
    $291.8M (the quarter ended 30 Jun 2020)
    Normal quarter (median of 8 earlier)
    $199.4M
    Typical spread (median absolute deviation)
    $18.9M
    How far from its usual level
    +3.3
    Same quarter last year
    $192.5M
    History used
    3,744 days
    2018-06-30: $201.9M2018-09-30: $197.0M2018-12-31: $180.6M2019-03-31: $180.5M2019-06-30: $192.5M2019-09-30: $224.8M2019-12-31: $256.4M2020-03-31: $294.1M2020-06-30: $291.8M
    the quarter ended 30 Jun 20208 earlier quartersnormal: $199.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 12 May 2020Financials change

    reported revenue of $294.1M for the quarter ended 31 Mar 2020, 1.6× the same quarter last year.

    Same quarter last year: $180.5M; its normal quarter is $199.4M.

    See the evidence
    This period
    $294.1M (the quarter ended 31 Mar 2020)
    Normal quarter (median of 8 earlier)
    $199.4M
    Typical spread (median absolute deviation)
    $12.9M
    How far from its usual level
    +4.7
    Same quarter last year
    $180.5M
    History used
    3,653 days
    2018-03-31: $205.0M2018-06-30: $201.9M2018-09-30: $197.0M2018-12-31: $180.6M2019-03-31: $180.5M2019-06-30: $192.5M2019-09-30: $224.8M2019-12-31: $256.4M2020-03-31: $294.1M
    the quarter ended 31 Mar 20208 earlier quartersnormal: $199.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 21 Feb 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 21 Feb 2020Filings record

    Director or officer change

  27. 14 Jan 2020Filings record

    Completed an acquisition or asset sale

  28. 14 Nov 2019Institutional holdings record

    COHEN & STEERS, INC. opened a $458.0M position (2019Q3 13F)

  29. 29 Aug 2019Filings record

    Completed an acquisition or asset sale

  30. 10 Aug 2019Insiders record

    DAWSON G STEVEN (director) bought 7,476 shares of MPW ($135,091) (dated 9 Aug 2019)

  31. 15 May 2019Institutional holdings change

    saw 80 13F filers open a new position in the quarter ended 31 Mar 2019, 2.3× the same quarter last year.

    Same quarter last year: 35; its normal quarter is 36.

    See the evidence
    This period
    80 (the quarter ended 31 Mar 2019)
    Normal quarter (median of 8 earlier)
    36
    Typical spread (median absolute deviation)
    6.5
    How far from its usual level
    +4.6
    Same quarter last year
    35
    History used
    2,008 days
    2017-03-31: 322017-06-30: 452017-09-30: 222017-12-31: 372018-03-31: 352018-06-30: 232018-09-30: 392018-12-31: 612019-03-31: 80
    the quarter ended 31 Mar 20198 earlier quartersnormal: 36

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  32. 14 Feb 2019Institutional holdings change

    saw 61 13F filers open a new position in the quarter ended 31 Dec 2018, 1.6× the same quarter last year.

    Same quarter last year: 37; its normal quarter is 34.

    See the evidence
    This period
    61 (the quarter ended 31 Dec 2018)
    Normal quarter (median of 8 earlier)
    34
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.6
    Same quarter last year
    37
    History used
    1,918 days
    2016-12-31: 332017-03-31: 322017-06-30: 452017-09-30: 222017-12-31: 372018-03-31: 352018-06-30: 232018-09-30: 392018-12-31: 61
    the quarter ended 31 Dec 20188 earlier quartersnormal: 34

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  33. 7 Sep 2018Filings record

    Completed an acquisition or asset sale

  34. 17 Jul 2018Insiders record

    DAWSON G STEVEN (director) bought 5,662 shares of MPW ($81,589) (dated 16 Jul 2018)

  35. 21 Feb 2018Filings record

    Director or officer change

  36. 5 Oct 2017Filings record

    Completed an acquisition or asset sale

  37. 6 Oct 2016Filings record

    Completed an acquisition or asset sale

  38. 23 Aug 2016Filings record

    Director or officer change

  39. 6 Apr 2016Filings record

    Director or officer change

  40. 29 Jan 2016Filings record

    Director or officer change

Not listed: 206 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001287865
Ticker
MPT
Domain
mpt.com
Hq location
AL|BIRMINGHAM| (1 unverified)
Lobbying client
goodwin procter llp o b o of medical properties trust, medical properties trust
Name
Bacoreta Investments S.L, Bath Business Management Limited, EDPA Propco-Rockledge, LLC, Healthcare Properties Fund Italy and 464 more
Wikipedia
Medical Properties Trust
  • Federal lobbying disclosures (LDA)2 records, 33 data points1 Aug 2023 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)172 records29 Jan 2016 to 6 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)847 data points31 Dec 2008 to 6 May 2026
  • SEC Form 4 insider transactions60 records, 216 data points1 Apr 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)54 data points13 Feb 2026 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)408 data points2 Feb 2026 to 20 Nov 2026
  • Wikipedia pageviews10 data points11 Nov 2026 to 20 Nov 2026